Astellas Home page | Astellas Pharma Inc.

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative ... ImportantNotice Thiswebsitecontainsinformationaboutproductsthatmaynotbeavailableinallcountries,ormaybeavailableunderdifferenttrademarks,fordifferentindications,orindifferentdosages.Nothingcontainedhereinshouldbeconsideredasolicitation,promotionoradvertisementforanydrugincludingtheonesunderdevelopmentonthiswebsite. Anyinformationontheproductscontainedhereinisnotintendedtoprovidemedicaladvicenorshouldbeusedasasubstitutefortheadviceprovidedbyyourphysicianorotherhealthcareprovider. OurUseofCookies InthisWebsite,informationcalledCookiesarestoredinthePCusedtobrowsethissite,forthepurposeofprovidingbettercontent.Pleasereadour TermsofUse formoreinformationonouruseofcookies.Byusingthissite,youacceptouruseofcookies. Accept ThankyouforvisitingtheAstellasPharmaInc.Website. Youwillenterexternalsitesbeyondhere.(Thislinkopensinanewwindow) CancelClickheretoleavethissite. Previous Pause Next AstellasDXStrategySeriesVol.3:ANewApproachtoClinicalTrialsPoweredbyPatientVoiceandTechnology ReadMore NewsRoomisnowavailable. ReadMore Astellas’PathtoSustainabilityVol.1:ANewMaterialityMatrixasaCompasstoDirectourBusiness ReadMore 1 2 3 News ALL PressReleases IR Stories News/PressReleasesSep13,2022Astellas,SeagenandMerckAnnounceResultsofClinicalTrialInvestigatingPADCEV®(enfortumabvedotin-ejfv)withKEYTRUDA®(pembrolizumab)andPADCEVasMonotherapyinFirst-LineAdvancedUrothelialCancerReadMore News/GeneralNewsSep12,2022AstellasUpdates“ContactforPotentialAcquisitionofAstellas’R&DPrograms”SectiononitsCorporateWebsiteReadMore News/PressReleasesSep05,2022AstellasAnnouncesToplineResultsfromPhase3Long-TermSafetyStudyofFezolinetantinMainlandChinaReadMore News/PressReleasesNov20,2019LaunchofEvrenzo®(roxadustat)TabletsinJapanfortheTreatmentofRenalAnemiainPatientsonDialysis-First-in-ClassOrallyAdministeredHIF-PHInhibitor-ReadMore News/GeneralNewsNov08,2019Technology×Healthcare2019-TheChallengetoEvolution:ConnectionbetweenHealthcareandTechnology-ReadMore News/IROct01,2019PostedPresentationSlidesforConferenceCallReadMore Viewmore>> News/PressReleasesSep13,2022Astellas,SeagenandMerckAnnounceResultsofClinicalTrialInvestigatingPADCEV®(enfortumabvedotin-ejfv)withKEYTRUDA®(pembrolizumab)andPADCEVasMonotherapyinFirst-LineAdvancedUrothelialCancerReadMore News/PressReleasesSep05,2022AstellasAnnouncesToplineResultsfromPhase3Long-TermSafetyStudyofFezolinetantinMainlandChinaReadMore News/PressReleasesAug18,2022U.S.FDAAcceptsAstellas’NewDrugApplicationforFezolinetantReadMore News/PressReleasesNov20,2019LaunchofEvrenzo®(roxadustat)TabletsinJapanfortheTreatmentofRenalAnemiainPatientsonDialysis-First-in-ClassOrallyAdministeredHIF-PHInhibitor-ReadMore News/PressReleasesJun17,2019LaunchofGonax®240mg(Newdosageform)inJapanforthetreatmentofprostateCancerReadMore News/PressReleasesJun07,2019Bisono®Tape2mg,aTransdermalPatchofβ1Blocker,LaunchedinJapanReadMore Viewmore>> News/IRAug01,2022PostedFinancialResultsfor1Q/FY2022ReadMore News/IRJun20,2022PostedNoticeofResolutionReadMore News/IRMay26,2022PostedNoticeofConvocationofthe17thTermAnnualShareholdersMeetingReadMore News/IROct01,2019PostedPresentationSlidesforConferenceCallReadMore News/IRMay22,2018Updated"StrategicPlan"SectionReadMore News/IRApr26,2018Updated"IRCalendar"SectionReadMore Viewmore>> News/StoriesAug19,2022Wepublishedastory:“AstellasDXStrategySeriesVol.3:ANewApproachtoClinicalTrialsPoweredbyPatientVoiceandTechnology”ReadMore News/StoriesJul07,2022Wepublishedastory:“AstellasDXStrategySeriesVol.2:DrugDiscoveryPlatformIntegratingHumans,AI,andRobots”ReadMore News/StoriesJun24,2022Wepublishedastory:“Astellas’PathtoSustainabilityVol.1:ANewMaterialityMatrixasaCompasstoDirectourBusiness”ReadMore Viewmore>> CorporateStrategicPlan2021  ReadMoreAccesstoHealth：OurInitiativesAdvancescontinuetobemadeintechnologyandmedicinethataddressunmetmedicalneeds.However,therestillremainbarriersformanypeoplewhohavedifficultyaccessingthehealthcaretheyneedduetothelackofavailabletreatments,poverty,healthcaresystemchallengesandinsufficienthealthcareinformation.ReadMoreHistoryAstellaswasestablishedin2005throughmergerofYamanouchiPharmaceuticalCo.,Ltd.andFujisawaPharmaceuticalCO.,Ltd.andhasarichhistoryspanningover100years.ReadMore AnnualReport2021AnnualReport2021IntegratedwiththeCSRreport. ModernSlaveryAct2015　　 CorporateProfileCompanybrochureisavailableinPDF. BusinessResultsLatestmaterialsonIRareavailablehere. ContactforPotentialAcquisitionofAstellas’R＆Dprograms. HomepageExternalLink Menu